Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in im… Read more
Prestige BioPharma Limited (950210) - Total Assets
Latest total assets as of September 2025: ₩714.76 Billion KRW
Based on the latest financial reports, Prestige BioPharma Limited (950210) holds total assets worth ₩714.76 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Prestige BioPharma Limited - Total Assets Trend (2018–2025)
This chart illustrates how Prestige BioPharma Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Prestige BioPharma Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Prestige BioPharma Limited's total assets of ₩714.76 Billion consist of 28.2% current assets and 71.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 15.6% |
| Accounts Receivable | ₩1.00 Billion | 0.1% |
| Inventory | ₩26.86 Billion | 3.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩182.02 Billion | 24.5% |
| Goodwill | ₩10.48 Billion | 1.4% |
Asset Composition Trend (2018–2025)
This chart illustrates how Prestige BioPharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prestige BioPharma Limited's current assets represent 28.2% of total assets in 2025, an increase from 12.4% in 2018.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2025, up from 9.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 24.5% of total assets.
Prestige BioPharma Limited Competitors by Total Assets
Key competitors of Prestige BioPharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Prestige BioPharma Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Prestige BioPharma Limited generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Prestige BioPharma Limited generates $ 3.00 in net profit.
Prestige BioPharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 1.41 | 5.88 |
| Quick Ratio | 0.96 | 1.30 | 5.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩24.92 Billion | ₩ 72.15 Billion | ₩ 41.33 Billion |
Prestige BioPharma Limited - Advanced Valuation Insights
This section examines the relationship between Prestige BioPharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | ₩741.92 Billion |
| Market Capitalization | $23.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prestige BioPharma Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Prestige BioPharma Limited's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Prestige BioPharma Limited (2018–2025)
The table below shows the annual total assets of Prestige BioPharma Limited from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | ₩741.92 Billion | +4.24% |
| 2024-06-30 | ₩711.72 Billion | -4.03% |
| 2023-06-30 | ₩741.60 Billion | +48.38% |
| 2022-06-30 | ₩499.81 Billion | -17.27% |
| 2021-06-30 | ₩604.17 Billion | +277.37% |
| 2020-06-30 | ₩160.10 Billion | +55.55% |
| 2019-06-30 | ₩102.92 Billion | +149.51% |
| 2018-06-30 | ₩41.25 Billion | -- |